Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
Joint Authors
Christoforidis, John Byron
Agrawal, Shivi
Joshi, Malav
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-11-06
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes.
Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases.
Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept.
The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance.
This paper focuses on sterile endophthalmitis.
In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.
American Psychological Association (APA)
Agrawal, Shivi& Joshi, Malav& Christoforidis, John Byron. 2013. Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy. Mediators of Inflammation،Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-510197
Modern Language Association (MLA)
Agrawal, Shivi…[et al.]. Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy. Mediators of Inflammation No. 2013 (2013), pp.1-6.
https://search.emarefa.net/detail/BIM-510197
American Medical Association (AMA)
Agrawal, Shivi& Joshi, Malav& Christoforidis, John Byron. Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy. Mediators of Inflammation. 2013. Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-510197
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-510197